Q2 Earnings Forecast for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Stock analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per share of ($0.04) for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.11 EPS, FY2026 earnings at $0.65 EPS and FY2029 earnings at $1.90 EPS.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Avadel Pharmaceuticals in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft initiated coverage on Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target for the company. UBS Group cut their price objective on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Piper Sandler decreased their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a research report on Wednesday, April 9th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $19.88.

Avadel Pharmaceuticals Trading Up 3.0 %

Shares of AVDL stock opened at $8.15 on Tuesday. Avadel Pharmaceuticals has a 12 month low of $6.38 and a 12 month high of $19.09. The firm has a market capitalization of $787.53 million, a PE ratio of -10.32 and a beta of 1.52. The firm has a fifty day simple moving average of $8.01 and a two-hundred day simple moving average of $10.03.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AVDL. FMR LLC bought a new position in shares of Avadel Pharmaceuticals in the third quarter worth $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Avadel Pharmaceuticals in the 3rd quarter worth about $484,000. State Street Corp grew its holdings in Avadel Pharmaceuticals by 42.5% during the 3rd quarter. State Street Corp now owns 1,623,302 shares of the company’s stock valued at $21,290,000 after buying an additional 483,787 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Avadel Pharmaceuticals during the third quarter valued at about $633,000. Finally, MML Investors Services LLC lifted its holdings in shares of Avadel Pharmaceuticals by 13.8% in the third quarter. MML Investors Services LLC now owns 136,356 shares of the company’s stock worth $1,788,000 after buying an additional 16,500 shares in the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Avadel Pharmaceuticals

In other Avadel Pharmaceuticals news, Director Linda Palczuk acquired 5,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were acquired at an average cost of $7.93 per share, with a total value of $39,650.00. Following the completion of the acquisition, the director now directly owns 67,900 shares in the company, valued at $538,447. This trade represents a 7.95 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.80% of the stock is owned by corporate insiders.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.